This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignees: Trimeris, Inc., Other. Active years: 2000-2009.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Chapel Hill, NC (US) (2000 - 2004)
- Langley, WA (US) (2009)
Company Filing History:
4 out of 31 
1 out of 834,513 Years Active: 2000-2009
Title: Innovator Myung-Chol Kang: A Pioneer in Antiviral Peptide Research
Introduction
Myung-Chol Kang, based in Chapel Hill, North Carolina, is a distinguished inventor recognized for his significant contributions to the field of antiviral research. With a portfolio of five patents, Kang’s work primarily focuses on the synthesis and application of antiviral peptides, showcasing his commitment to advancing medical science and combating viral infections.
Latest Patents
Kang's recent innovations include two notable patents. The first is an "Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides". This invention outlines conjugates that consist of a polymer operably bound to multiple synthetic peptides derived from HIV gp41. The conjugates are designed to inhibit the transmission of HIV to target cells, presenting methods to prevent viral infection effectively.
The second patent involves "Methods and compositions for peptide synthesis". This invention focuses on the synthesis of T-1249 and T-1249-like peptides using solid and liquid-phase synthesis procedures. It details methods for combining specific peptide fragments to yield the desired peptides and identifies peptide fragments that serve as intermediates, ultimately contributing to the production of full-length T-1249 peptides.
Career Highlights
Throughout his career, Myung-Chol Kang has worked with prominent companies in the biotechnology sector, including Trimeris, Inc. His expertise has contributed to various projects and innovations, enhancing his standing as a notable figure in peptide research and antiviral therapies.
Collaborations
Kang has collaborated with esteemed professionals in his field, including Brian L. Bray and Maynard Lichty. These partnerships have further enriched his research endeavors and have contributed to his success in obtaining patents that underscore the importance of collaborative innovation in science.
Conclusion
Myung-Chol Kang exemplifies the spirit of innovation in the field of antiviral research. Through his patents and collaborative efforts, he continues to make strides in developing new methodologies and conjugates that hold promise in the fight against HIV. His work not only represents significant advancements in the field but also illustrates the critical role of inventors in improving global health outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile